BPC
MRTX

Banque Pictet & Cie’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Banque Pictet & Cie’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,941
Closed -$407K – 628
2023
Q1 		$407K Sell
10,941
-4,961
-31% -$223K ﹤0.01% 494
2022
Q4 		$721K Sell
15,902
-5,018
-24% -$325K 0.01% 445
2022
Q3 		$1.46M Sell
20,920
-6,597
-24% -$488K 0.02% 336
2022
Q2 		$1.85K Buy
27,517
+14,142
+106% +$899K 0.02% 314
2022
Q1 		$1.1M Buy
13,375
+518
+4% +$53K 0.01% 430
2021
Q4 		$1.89M Buy
+12,857
New +$2M 0.01% 364

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Banque Pictet & Cie's MRTX Position: Q2 2023 in Review

Banque Pictet & Cie sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 10,941 shares — an estimated $407K sold.

Banque Pictet & Cie first reported a position in MRTX in Q4 2021 and held it in 6 quarters. The position peaked at $1.89M in Q4 2021. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

  • Banque Pictet & Cie reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Banque Pictet & Cie sold 10,941 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $407K.
  • Banque Pictet & Cie first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
  • Banque Pictet & Cie's Mirati Therapeutics, Inc. Common Stock position peaked at $1.89M in Q4 2021.
  • 207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Banque Pictet & Cie's 13F filing for Q2 2023, filed 4 Aug 2023.